HuagongsheHuagongshe Chemistry Print Report · For research reference only
Acetate → Bupropion
Participants
| Role | Name | HCID | Charge |
|---|---|---|---|
| Reactant | Acetate | HCID 175 | — |
| Reactant | Phosphate | HCID 1061 | — |
| Reactant | Bupropion Hydrochloride | HCID 62884 | — |
| Reactant | Bupropion Hydrobromide | HCID 11984562 | — |
| Product | Bupropion | HCID 444 | — |
Reaction Steps
The dissolution of bupropion HBr formulations according to the invention were assessed in three USP-3 media, i.e., SGF pH 1.2, Acetate Buffer pH 4.5 and Phosphate Buffer pH 6.8 over a period of 16 hours. These results are contained in FIG. 66. Particularly Bupropion HBr XL 348 mg tablets (final), Lot # Bup-HBr-XL-012-5; Wellbutrin XL 300 mg tablets (final), Lot # 05A116; Bupropion HBr XL 348 mg tablets ECl Lot # Bup-HBr-XL-012-5 (EC 32 mg wg) and Wellbutrin XL 300 mg tablets (EC10-Lot # 05D047 were assessed in SGF media pH 1.2 for 2 hours, Acetate Buffer pH 4.5 for 2 hours, and Phosphate Buffer SIF pH 6.8 for a total of 10 hours. The results are contained in the FIG. 66-68.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| Patent number | US07563823B2 |
| Source dataset | uspto-grants-2009_07 |
| ORD ID | ord-40e1bbce3083436c940deac123c8d01f |
| Source note | uspto-grants-2009_07 |